Introduction
The most recent World Health Organization (WHO) data estimate that 35.2 million new gonorrhoea infections occur in the Western Pacific Region annually, representing approximately 40% of the global burden of new gonorrhoea infections (1) .
Gonorrhoea is caused by infection with the bacterium Neisseria gonorrhoeae. Therefore, effective antibiotic treatment is a key component of strategies for gonorrhoea disease control and prevention. Over time, N. gonorrhoeae has developed antibiotic resistance a to each successive therapeutic recommendation, leaving limited options for treatment and raising high-level concerns for the future management of this infection.
WHO has defined criteria for decreased susceptibility to cephalosporin antibiotics and defined N. gonorrhoeae treatment failure (Box 1 and 2). The emergence of antimicrobial resistance (AMR) b presents a threat to global health security. In 2013, the United States Centers for Disease Control and Prevention (CDC) elevated the threat level of antibiotic-resistant N. gonorrhoeae to urgent (2) , and in September 2016, global leaders met to address the seriousness of the situation at the United Nations General Assembly. The WHO Gonococcal Antimicrobial Surveillance Programme (GASP) for the Western Pacific Region has been monitoring gonococcal AMR in the Region since 1992.
Gonococcal AMR in the Western Pacific Region -the current situation
Over time, antibiotics from four classes -penicillins, tetracyclines, fluoroquinolones and cephalosporins -have been sequentially recommended as first-line treatment for gonorrhoea, with changes in recommendations driven by the emergence and persistence of resistance.
Resistance to penicillin and tetracycline was first reported in the United States of America and Europe (3) and is now highly prevalent worldwide with few exceptions. Resistance to fluoroquinolone was widespread in countries and areas in the Western Pacific Region by the 1990s (3). More recently, ceftriaxone-resistant strains of N. gonorrhoeae have been reported in Japan and Australia (4), and globally there have been increasing reports of N. gonorrhoeae resistance to azithromycin (5) (6) (7) . The H041 strain of N. gonorrhoeae that is resistant to extended spectrum cephalosporins was isolated in Japan in 2009 (8, 9) , and the genetically similar A8806 strain was identified in Australia in 2013. Today, ciprofloxacin and penicillin resistance is widespread in most countries and areas in the Western Pacific Region, with the exception of remote parts of Australia and New Caledonia, and isolates with decreased susceptibility to ceftriaxone and azithromycin (Table 1) Antimicrobial resistance (AMR) is the ability of a microorganism (like bacteria, viruses, and some parasites) to stop an antimicrobial (such as antibiotics, antivirals and antimalarials) from working against it. As a result, standard treatments become ineffective, infections persist and may spread to others.
Key messages:
1. Ciprofloxacin, tetracycline and penicillin resistance is highly prevalent in the Western Pacific Region with the exception of remote areas in Australia and New Caledonia.
2.
Neisseria gonorrhoeae isolates with decreased susceptibility to ceftriaxone and azythromycin are widely reported.
3.
Increasing the coverage of antimicrobial resistance (AMR) surveillance in the Western Pacific Region is critical to inform treatment guidelines and to monitor AMR. 
Challenges and next steps
The threat of emergence of resistance to cephalosporins is of great concern as there are limited alternative treatment options for gonorrhoea. Gaps in surveillance data limit the understanding of the epidemiology of gonococcal AMR. There are limited or no AMR data available from some countries for manifold reasons including syndromic management (therefore no antibiotic susceptibility testing), lack of capacity and/or resourcing for antibiotic susceptibility testing, limited access to laboratories and services, and the use nucleic acid amplification tests by preference or necessity in place of culture for detection of gonorrhoea. Further, with regard to management, many Member States are lower middle-income countries, and the supply of antibiotics, and adherence to recommended guidelines, are subject to challenges in resourcing and national policy. Only a few countries are on track in adopting new WHO treatment recommendations.
As comprehensive data on gonococcal AMR are necessary for planning and resource allocation, both materially and technologically, increasing the coverage of WHO GASP in the Western Pacific Region is a priority. In addition to expanding culture and MIC capability, there is a need to look to newer tests to enhance AMR surveillance. Molecular assays have been developed to detect N. gonorrhoeae AMR markers and implementing these can increase the evidence base for treatment guidelines, particularly in settings where culture is limited. Recent work in Australia has demonstrated the efficacy and impact of these assays in remote settings (11, 12) .
AMR data are urgently needed to respond to changes in resistance patterns and to inform the management guidelines.
In line with GLASS, WHO has embarked on the development of standardized drug resistance surveillance protocols in selected countries. Exploring substitutes for the extended spectrum cephalosporin antibiotics as first-line treatment for this infection is on the global health and research agenda. Increasing the coverage of AMR surveillance in the Western Pacific Region is critical to inform treatment guidelines and to monitor AMR. Strengthening coverage and reach of primary prevention strategies continues to be an essential public health priority. a Spectinomycin is NOT registered in Hong Kong SAR (China) but can be accessed via a local system of "named patient base". b Treatment depends on culture and sensitivity result given that ~ 10% and 20% of the local strains are resistant to azithromycin in Hong Kong SAR (China) respectively.
c Ciprofloxacin was recommended when resistance testing was available in New Zealand.
